We have developed a new radioligand binding assay method to measure the concentration of non-radiolabeled drugs in the brain ex vivo. This new method fuses the concepts of standard competition and saturation binding assays, and utilizes a transformed version of the Cheng-Prusoff equation to calculate the drug concentration. After testing the validity of this method, we demonstrated its utility by measuring the brain concentration of sazetidine-A, a newly developed nicotinic receptor ligand, and its elimination rate after a single subcutaneous administration. Our results indicate that sazetidine-A reaches brain concentrations that are known to occupy and desensitize the majority of nAChR binding sites. Furthermore, using this method, we estimated the half-life of sazetidine-A in the rat brain to be ~65 min. It is important to note that the method described here to measure sazetidine-A in brain should be generalizable to other drugs acting at any receptor that can be reliably measured with a radiolabeled ligand.
Introduction
Sazetidine-A (saz-A) is a recently developed partial agonist that potently desensitizes β 2-containing nAChRs (Xiao et al., 2006; Zwart et al., 2008) and produces interesting behavioral effects in rodents. For example it decreases nicotine and alcohol self-administration in rats (Levin et al., 2010; Rezvani et al., 2010; Johnson et al., 2012) , improves performance on tasks of attention even in rats treated with the NMDA receptor blocker dizocilpine (MK801) or the muscarinic receptor blocker scopolamine (Rezvani et al., 2011) , and decreases anxiety-and depression-like behavior in mice (Kozikowski et al., 2009; Turner et al., 2010; Caldarone et al., 2011) .
In contrast to the substantial behavioral pharmacology profile of saz-A that is emerging, little is known about its concentrations in blood and brain or its pharmacokinetic properties in the rat. A recent study of the antidepressant-like effects of saz-A used reverse phase highperformance liquid chromatography (HPLC) to measure the pharmacokinetic properties of saz-A and autoradiography to measure the time course of its receptor occupancy in the mouse (Caldarone et al., 2011) . The results indicated that although saz-A was rapidly eliminated from both the brain and plasma following a single intraperitoneal (ip) injection, it occupied the majority of nAChR binding sites for 8 hr or longer. This long-term receptor occupancy is likely due to the high affinity of saz-A at α 4β2 nAChR binding sites and its very slow dissociation rate.
Here, to complement the behavioral studies with saz-A that have been carried out in rat models (Levin et al., 2010; Rezvani et al., 2010; Rezvani et al., 2011; Johnson et al. , 2 012), we describe its pharmacokinetic properties in rats. To measure the concentration and elimination rate of saz-A in blood serum, we used a radioligand binding assay that was originally developed to measure the serum concentrations of dopaminergic drugs (Creese and Snyder, 1977) . To
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J P E T # 1 9 8 0 6 9 5 measure the concentration of saz-A in brain, we developed a new radioligand receptor binding assay method that combines concepts from competitive and saturation receptor binding. Thus, we called this new assay "competitive-saturation binding". Furthermore, to actually calculate the concentration of saz-A in this new assay, we derived a transformed version of the ChengPrussoff equation (Cheng and Prusoff, 1977 
Saz-A administration:
Saz-A was dissolved in sterile saline, and the pH was adjusted to 6.5 -8.0 with NaOH. Drug was delivered by subcutaneous (sc) injections above the shoulders.
Doses of sazetidine-A dihydrochloride are reported as the salt.
Preparation of unwashed cerebral cortex homogenates: Ten min after administration f the drug, the rats were anesthetized with isoflurane, decapitated, and the brains were dissected on ice. Dissected cortex was suspended in ~20 volumes of 50 mM Tris HCL buffer (pH 7.4) and then homogenized with a Glass/Teflon homogenizer (6-7 strokes) followed by a 10 sec This article has not been copyedited and formatted. The final version may differ from this version. Prism 5. The IC 50 of saz-A was determined from the fitted curve and the K i was calculated from the Cheng-Prusoff equation (Cheng and Prusoff, 1973) .
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Results
We developed a sensitive radioligand binding method that fuses principles of receptor saturation and competition assays to measure the concentration of drugs in brain and/or other tissues that contain receptors that bind radioligands with high affinity. We validated this new method and used it to measure the concentration of saz-A in rat brain.
Competitive-saturation binding. The method to measure saz-A is based on a standard Prusoff equation (Cheng and Prusoff, 1973) Fig 1A) . The K d , of [ 3 H]EB in the absence of saz-A, was calculated to be 61 pM in unwashed cortical homogenates (Fig 1B) . When 3.5 nM saz-A was added to these homogenates, the apparent affinity of [ 3 H]EB, K dA , was calculated to be 540 pM. By using these values in the transformed Cheng-Prussoff equation (Fig 2A, equation 2b the homogenization of the tissue was not included because the drug was added directly to the tissue after homogenization.
To further test the accuracy and precision of this method, unwashed cortical homogenates were incubated with 9 different known concentrations of saz-A. [ 3 H]EB saturation binding was then carried in these homogenates, and the concentrations of saz-A were calculated from the fitted competitive-saturation curves, as described above. Figure 2C shows the relationship of the calculated concentrations of saz-A plotted against the known concentrations of saz-A that were actually added to the homogenates. As the plotted data fall close to the line of identity, this homogenates, and then the further dilution of these homogenates in the binding assay. Using this competitive-saturation method, the final concentration of saz-A in the brain was calculated to be ~187 nM.
Serum was also prepared from the same rats that received saline or saz-A (2mg/kg)
injections. The concentration of saz-A in the serum was measured by another radioligand binding assay, which was adapted from a method originally developed by Creese and Snyder (1977) Figure 3B shows the normalized percent The radioligand binding approaches were also used to measure the elimination rate of saz-A from the brain and serum. Adult male rats were sacrificed at varying time points (10 -120 min) following a single sc injection of saline or saz-A (2 mg/kg). The concentration of saz-A was then measured in the cortex by competitive saturation binding, and in the serum by competition binding, as described above. The results from this experiment (Fig 4) indicate that This article has not been copyedited and formatted. The final version may differ from this version.
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J P E T # 1 9 8 0 6 9 1 5 saz-A reached a peak concentration of ~150 nM in the brain and ~1.6 μ M in serum. Following the peak concentration, saz-A was eliminated from both the brain and serum with a calculated half life (t 1/2 ) of ~65 min. Taken together, these results indicate that saz-A is not concentrated in brain and, in fact, displays a limited ability to enter the brain; furthermore, it is eliminated relatively rapidly. Nevertheless, the peak concentration of saz-A in the brain after sc injection of 2 mg/kg is ~ 1,000 times its K i value for α 4β2* nAChRs; thus, this concentration of saz-A should occupy virtually all of these receptors in the brain.
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Discussion
In this study, we describe a new, relatively simple radioligand receptor binding assay and derived a transformed version of the Cheng-Prussoff equation (Cheng and Prussoff, 1973) theoretically, this method can be used to assess the concentration of any drug in any tissue, as long as the drug reaches a sufficient concentration in the tissue to compete for a receptor that can be accurately and reliably measured with a radioligand. In practice this means that after dilution the drug has to reach a concentration in the binding assay equal to or greater than its dissociation constant, K i . To some extent, if increased sensitivity is required, tissue can be added to the competitive-saturation binding assay at a higher concentration, which would result in less dilution of the drug of interest. For example, in determining the brain concentration of saz-A after the acute injection done here, the tissue and drug were diluted a total of 50-fold (20-fold dilution in making the tissue homogenate and a 2.5-fold dilution in adding the homogenate to the binding assay), but this total dilution could have been reduced to 12.5-fold by using a lower volume in the initial homogenization and reducing the volume of the binding assay. Together, this change in dilution would result in a 4-fold increase in sensitivity. Thus, this method is potentially sensitive enough to measure the concentrations of certain drugs in the sub-nanomolar range (e.g., Fig. 2C ), which in some cases may be below the limits of reliable measurements with other methods.
Here we show that competitive-saturation binding is both accurate and precise at measuring known concentrations of saz-A that were added to brain homogenates (Fig 2C) . The utility of this assay was demonstrated by measuring saz-A in the brain after a single sc injection and comparing it to the concentration of saz-A in rat serum, measured by a competitive radioligand binding assay (Fig. 3) . Our results indicate that 10 min following a single sc injection (2mg/kg), saz-A reached brain and serum concentrations of ~190 nM and ~1.3
respectively. This difference in brain versus serum concentrations indicates that saz-A probably does not enter brain easily nor concentrate there. Nevertheless, as indicated above, this concentration of saz-A is ~1000 times its K i for α 4β2* nAChRs, thus it should occupy nearly all of these receptors in the brain. A previous study (Caldarone et al., 2011) , which used HPLC methods to measure the concentration of saz-A in mouse brain and plasma, reported that 15 min following a single ip injection of 3 mg/kg, saz-A reached brain and plasma concentrations of ~38 nM and ~240 nM, respectively. Although these values in mice are lower than the values we measured in rats, the ratio of brain to blood concentrations are similar, 0.16 in mice and 0.13 in rats. The differences in concentration values could be a result of differences in drug metabolism between species, differences in drug bioavailability after ip injections compared to sc injections, and/or differences in the time of measurements. Moreover, in that study even the lower concentration of saz-A found in mouse brain occupied ~90% of the nAChRs (Caldarone et al., 2011) .
In a companion paper (Hussmann et al., currently under review), we used this competitive-saturation method to measure the brain concentrations of saz-A, nicotine and varenicline 10 min after a series of chronic sc injections, and we compared these concentrations to the steady-state brain concentrations when the drugs were administered via osmotic This article has not been copyedited and formatted. The final version may differ from this version. (Ghosheh et al., 1999; Doura et al., 2008; Rollema et al., 2010) .
We also used radioligand binding approaches to measure the elimination rate of saz-A from rat brain. We found that after a single sc injection (2mg/kg), saz-A displayed a half-life of ~65 min in brain and serum. Caldarone et al (2011) measured a somewhat faster elimination rate of saz-A from mouse brain and plasma after ip administration, which again might be attributable to species differences and/or to the different routes of administration. Interestingly, in mice, despite the rapid elimination of saz-A from the brain as a whole, receptor occupancy appeared to be > 60% for at least 8 h (Caldarone et al., 2011 ).
As indicated above, the competitive-saturation binding method is sensitive, accurate and versatile in that theoretically it can be used to measure the concentration of any drug/ligand that competes with high affinity for receptor(s) that can be radiolabeled. A limitation of this method, as with all known analytical methods, is that it does not distinguish between intracellular and extracellular drug concentrations. A conceivable disadvantage of this method is that it doesn't measure the actual chemical species of the drug/ligand itself but instead reflects the binding of the ligand to the receptor, from which the concentration can be deduced. Thus, the concentration of two or more ligands that competitively bind at the same receptor site in the same tissue would not be distinguishable. For example, if a single drug is metabolized to a compound that also has a high binding affinity for the receptor target, the concentration of the metabolite would be compound is inactive. Thus, the assay could be used to screen for unidentified active metabolites. Furthermore, the assay allows the measurements of competitive drug binding at multiple receptor targets in the same tissues.
Finally, an additional advantage of competitive-saturation binding is that it is easy to carry out. Unlike HPLC methods, the drug of interest is not extracted and/or purified from the tissue before measurements. Both the drug and receptor source are provided in the tissue homogenates, so only the radioligand needs to be added to carry out the assay. Again, this method can be used to measure any drug in the brain or other tissue, as long as the drug of interest reaches a concentration equal to or greater than its K i after dilution in the binding assay, and a competitive radioligand for the target receptor is available. Thus, competitive-saturation binding should be a useful and convenient method for measuring drug concentrations, as well as the pharmacokinetics of drugs in the brain and other tissues.
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